IBD Science for Patients

New Study Reassures Patients about JAK Inhibitor Safety

When you and your doctor are deciding on a treatment for ulcerative colitis (UC), safety is often the first thing on your mind. You might have heard about a type of medicine called a JAK inhibitor (like tofacitinib) and wondered if it is as safe as the more common biologic treatments (like infliximab).

A major new study has provided some of the most reassuring evidence yet. By looking at “real-world” data from thousands of people in the United States, researchers found that the risks of serious heart problems, strokes, and infections are very similar across both types of medicine.

What the Research Found

Scientists carried out a large-scale retrospective claims analysis. This means they used computers to scan through a massive database of US insurance records to see what happened to patients after they started their medicine.

The study compared patients taking tofacitinib (a twice-daily pill) with those taking biologics. They were looking for four specific “serious events”:

  1. Serious Infections: Infections that required a stay in hospital.
  2. Myocardial Infarction: The medical term for a heart attack.
  3. Stroke: When blood flow to the brain is interrupted.
  4. Thromboembolic Events: Dangerous blood clots in the legs or lungs.

The results showed no significant difference in the risk of these events between tofacitinib and biologics. This suggests that for most people with UC, tofacitinib is just as safe a choice as the biologics we have been using for decades.

Study Scale and Details

This was a large-scale investigation using “Big Data.” While the exact number of thousands of patients varies by database, these types of “claims analyses” typically involve tens of thousands of people. The study looked at several years of medical records to ensure they had a clear picture of how these drugs behave in the real world, rather than just in a controlled laboratory setting.

Why This Matters to You as a Patient

This research is a big win for patient choice and personalised medicine.

  • Reassurance and Peace of Mind: If you prefer taking a pill rather than having an injection, this study gives you the scientific proof that you aren’t necessarily taking a higher safety risk to get that convenience.
  • More Tools in the Box: Ulcerative colitis can be stubborn. Knowing that tofacitinib has a safety profile similar to biologics means you have another powerful tool to reach remission without extra fear.
  • Individual Risk Still Counts: While the average risk is the same, your own health history (like your age or whether you smoke) still matters. This study helps you and your doctor have a better conversation about which treatment is the best match for you based on your specific body.

While doctors should always keep a close eye on any patient starting a new treatment, this “Big Data” check-up suggests that our modern UC medicines are working safely for the vast majority of people.

Explore the Research

Leave a comment